Search - tctmd.com

Displaying 1 - 20 of 63

Sort: Relevancy | Date

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

December 30, 2016

News Features

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

December 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

December 29, 2016

News Opinion Editor's Corner

Las Noticias y Blogs Más Populares de TCTMD en 2016

December 29, 2016

News Daily News

AHA/ACC Report Recommends 10 Measures to Prevent Sudden Cardiac Death

December 23, 2016

News Daily News

Patients With A-fib Still Have High Mortality Risk After Appropriate Anticoagulation Is Started

December 05, 2016

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

November 29, 2016

News Conference News AHA 2016

Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias

November 21, 2016

News Conference News AHA 2016

Subclinical A-fib Common in Older, Asymptomatic Patients

November 18, 2016

News Conference News AHA 2016

La FA Subclínica es Común en Pacientes Asintomáticos de Mayor Edad

November 18, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

November 09, 2016

Conduction Problems Requiring Permanent Pacemakers Continue to Vex TAVR Field

News Daily News

Conduction Problems Requiring Permanent Pacemakers Continue to Vex TAVR Field

November 08, 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

November 07, 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presentation TCT 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx

November 01, 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presentation TCT 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson

November 01, 2016

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

Presentation TCT 2016

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt

November 01, 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presentation TCT 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran

November 01, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.